MX2011006150A - Compuestos inhibidores de cinasa. - Google Patents

Compuestos inhibidores de cinasa.

Info

Publication number
MX2011006150A
MX2011006150A MX2011006150A MX2011006150A MX2011006150A MX 2011006150 A MX2011006150 A MX 2011006150A MX 2011006150 A MX2011006150 A MX 2011006150A MX 2011006150 A MX2011006150 A MX 2011006150A MX 2011006150 A MX2011006150 A MX 2011006150A
Authority
MX
Mexico
Prior art keywords
kinase inhibitor
inhibitor compounds
compounds
jak2
disorder
Prior art date
Application number
MX2011006150A
Other languages
English (en)
Inventor
Peter P Sayeski
Gyorgy M Keseru
Kirpal Bisht
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Publication of MX2011006150A publication Critical patent/MX2011006150A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/50—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/16—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring not being further substituted
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La descripción se refiere a compuestos novedosos que son capaces de modular las actividades de Jak2 cinasa, compuestos que tienen uso terapéutico para tratar o prevenir a un sujeto que sufre de o es susceptible a una enfermedad o trastorno mediado por Jak2, y métodos de uso y sus composiciones.
MX2011006150A 2008-12-09 2009-12-09 Compuestos inhibidores de cinasa. MX2011006150A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20140608P 2008-12-09 2008-12-09
PCT/US2009/067402 WO2010068710A2 (en) 2008-12-09 2009-12-09 Kinase inhibitor compounds

Publications (1)

Publication Number Publication Date
MX2011006150A true MX2011006150A (es) 2012-02-08

Family

ID=42243304

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011006150A MX2011006150A (es) 2008-12-09 2009-12-09 Compuestos inhibidores de cinasa.

Country Status (12)

Country Link
US (1) US20110301159A1 (es)
EP (1) EP2376425A4 (es)
JP (1) JP2012511585A (es)
KR (1) KR20110102405A (es)
CN (1) CN102395557A (es)
AU (1) AU2009324679A1 (es)
BR (1) BRPI0922880A2 (es)
CA (1) CA2746422A1 (es)
IL (1) IL213464A0 (es)
MX (1) MX2011006150A (es)
SG (1) SG172057A1 (es)
WO (1) WO2010068710A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895291B2 (en) 2010-10-08 2014-11-25 Terumo Bct, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
US20140248634A1 (en) * 2011-07-29 2014-09-04 University Of Florida Research Foundation Vimentin as a biomarker for the progression of myeloproliferative neoplasms
US20160123982A1 (en) 2013-02-04 2016-05-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for assaying jak2 activity in red blood cells and uses thereof
US9458086B1 (en) * 2013-07-03 2016-10-04 University Of South Florida (A Florida Non-Profit Corporation) Compositions and methods for adipocyte modulation
US9617506B2 (en) 2013-11-16 2017-04-11 Terumo Bct, Inc. Expanding cells in a bioreactor
EP3613841B1 (en) 2014-03-25 2022-04-20 Terumo BCT, Inc. Passive replacement of media
US9968566B2 (en) * 2014-08-28 2018-05-15 Keio University Pharmaceutical composition for prophylaxis and/or treatment of corneal and conjunctival diseases or presbyopia containing stilbene compound as active ingredient
JP6520019B2 (ja) * 2014-08-28 2019-05-29 学校法人昭和大学 新規スチルベン誘導体
CN106715676A (zh) 2014-09-26 2017-05-24 泰尔茂比司特公司 按计划供养
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
US11702634B2 (en) 2017-03-31 2023-07-18 Terumo Bct, Inc. Expanding cells in a bioreactor
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US20200088732A1 (en) 2017-04-13 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Mèdicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
DK3774736T3 (da) * 2018-03-27 2023-01-30 Neuropore Therapies Inc Forbindelser som modulatorer af TLR2-signalering
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2485550A (en) * 1946-06-25 1949-10-25 Hoffmann La Roche Quaternary salts of carbamic acid esters of tertiary-hydroxybenzyl-amines
US2750416A (en) * 1950-12-21 1956-06-12 Rohm & Haas Aminomethylphenols and method for their preparation
US3001999A (en) * 1955-12-01 1961-09-26 Geschickter Fund Med Res Products of phenol derivatives with formaldehyde and amines
GB872371A (en) * 1958-07-07 1961-07-05 Univ Kansas Reseach Foundation Benzyl amine compounds and means of obtaining the same
US3077470A (en) * 1961-03-21 1963-02-12 Univ Kansas Res Foundation 3-[4-hydroxy-3-(aminomethyl)-phenyl]-4-(4-oxyphenyl)-alkanes and alkenes
US3082113A (en) * 1961-05-03 1963-03-19 Dow Chemical Co Method for improving physical properties of clays and clay-containing soils and compositions resulting therefrom
US3752830A (en) * 1971-02-04 1973-08-14 Warner Lambert Co Substituted pyrano(2,3-b)pyrans
US3794734A (en) * 1971-03-03 1974-02-26 Merck & Co Inc Methods of treating edema and hypertension using certain 2-aminoethylphenols
US3849116A (en) * 1971-07-23 1974-11-19 Stanford Research Inst Boron binding plant growth agents
DE2325927A1 (de) * 1973-05-22 1974-12-19 Bayer Ag Neue carbamidsaeureester und verfahren zu ihrer herstellung
US3928624A (en) * 1974-04-25 1975-12-23 Merck & Co Inc Phenol compounds in treating pain, fever and inflammation
DE3039087A1 (de) * 1980-10-16 1982-05-19 Hoechst Ag, 6000 Frankfurt 1-(1,3-dioxolan-2-ylmethyl)-azole, ihre salze, verfahren zu ihrer herstellung und ihre verwendung
US4537920A (en) * 1983-08-18 1985-08-27 Ethyl Corporation 4H-1-benzopyrans and lubricant compositions containing same
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
JPH0656508B2 (ja) * 1985-01-26 1994-07-27 キヤノン株式会社 静電荷像現像用正摩擦帯電性トナー
US4792355A (en) * 1987-01-20 1988-12-20 Ford Motor Company Corrosion inhibiting aqueous, acidic compositions comprising metal-chelating omicron-hydroxybenzylamine compound
IT1238375B (it) * 1989-11-17 1993-07-16 Genego Spa Colonna di immunoaffinita' per l'estrazione simultanea di piu' residui di ormoni anabolizzanti da liquidi biologici e procedimento per la sua preparazione.
PE8798A1 (es) * 1995-07-17 1998-03-02 Pfizer Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil]
JP3876485B2 (ja) * 1996-08-27 2007-01-31 住友化学株式会社 亜リン酸エステル類、その製法及びその用途
GB9809207D0 (en) * 1998-04-29 1998-07-01 Bp Chem Int Ltd Novel catalysts for olefin polymerisation
CA2430376A1 (en) * 2000-12-08 2002-06-13 David J. Carini Semicarbazides and their uses as cyclin dependent kinase inhibitors
CA2466240A1 (en) * 2001-10-09 2003-04-17 Ciba Specialty Chemicals Holding Inc. Polyester and polyamide compositions of low residual aldehyde content
CN1186694C (zh) * 2002-12-05 2005-01-26 王柏枝 印刷制版方法及其印刷版
JP4099432B2 (ja) * 2003-06-20 2008-06-11 日本ポリプロ株式会社 オレフィン重合用触媒成分及び触媒
US20060166936A1 (en) * 2004-10-29 2006-07-27 Hayley Binch Diaminotriazole compounds useful as inhibitors of protein kinases
UY29223A1 (es) * 2004-11-23 2006-06-30 Astrazeneca Ab Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación
WO2008136173A1 (ja) * 2007-04-20 2008-11-13 Ochanomizu University スチルベン誘導体を有効成分とする脂肪細胞分化抑制剤
US7781580B2 (en) * 2007-04-23 2010-08-24 Virginia Commonwealth University Stilbene derivatives as new cancer therapeutic agents
WO2008153900A1 (en) * 2007-06-06 2008-12-18 University Of Florida Research Foundation Kinase inhibitor compounds
US8716355B2 (en) * 2007-06-20 2014-05-06 Kent State University Hydroxylated tolans and related compounds in the treatment of a cancer

Also Published As

Publication number Publication date
AU2009324679A1 (en) 2011-07-28
EP2376425A2 (en) 2011-10-19
CA2746422A1 (en) 2010-06-17
CN102395557A (zh) 2012-03-28
WO2010068710A3 (en) 2010-09-30
EP2376425A4 (en) 2012-12-26
US20110301159A1 (en) 2011-12-08
BRPI0922880A2 (pt) 2018-07-24
IL213464A0 (en) 2011-07-31
WO2010068710A2 (en) 2010-06-17
KR20110102405A (ko) 2011-09-16
JP2012511585A (ja) 2012-05-24
SG172057A1 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
MX2011006150A (es) Compuestos inhibidores de cinasa.
TW200801021A (en) Imidazolothiazole compounds for the treatment of disease
WO2010118063A3 (en) Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
MX2009007944A (es) Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
MX2010010317A (es) Compuestos heterociclicos novedosos y usos de los mismos.
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
JO3002B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
WO2010009342A3 (en) Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
WO2009044173A3 (en) Methods of treating cancer using notch pathway inhibitors
MX2009011951A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
MY191825A (en) Therapeutic compounds and compositions
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
MX2020009397A (es) Composiciones y metodos para inhibicion de la via jak.
MY159491A (en) Disubstituted phthalazine hedgehog pathway antagonists
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX2009011952A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
MX2009006812A (es) Moduladores del receptor c3a y metodos de uso de los mismos.
TN2011000166A1 (en) Disubstituted phthalazine hedgehog pathway antagonists
UA108878C2 (ru) Ингибиторы протеинтирозинкиназной активности
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
MX340807B (es) Nuevas composiciones para prevenir y/o tratar trastornos degenerativos del sistema nervioso central.
MX2010007669A (es) Metodos para inhibir la angiogenesis utilizando antagonistas de egfl8.
WO2009011910A3 (en) Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment

Legal Events

Date Code Title Description
FA Abandonment or withdrawal